Data on the Company's Holistic Portfolio Will Include
Real-World Data on MiniMed™ 780G System
and New Data on Medtronic Continuous Glucose Monitoring Systems and
Extended-Wear Infusion Set
DUBLIN, June 1, 2021 /CNW/ -- Medtronic
plc (NYSE:MDT), the global leader in medical technology, today
announced its virtual participation at the 14th International
Conference on Advanced Technologies & Treatments for Diabetes
(ATTD), taking place June 2-5, 2021.
Medtronic will showcase clinically meaningful outcomes associated
with the company's comprehensive product portfolio and future
technologies, as well as customer-centric support and services
provided in a remote environment during the COVID-19 pandemic,
including onboarding and training for healthcare providers and
patients.
Scientific Presentations
The following poster and oral
scientific data presentations represent the work of Medtronic
employees and independent investigators using Medtronic devices in
their research. Poster presentations will be available to all
attendees for viewing with an option to query presenters throughout
the conference.
MiniMed™ 780G System Poster Presentations
- "Cost-effectiveness of MiniMed™ 780G versus multiple daily
injections with intermittently scanned continuous glucose
monitoring in individuals with type 1 diabetes in Austria" – oral presentation by Ohad Cohen, M.D. on Wednesday, June 2 at 1:20
p.m. CT (20:20 CET).
- "Early glycemic effects among Pediatric (7-17 years) and Adult
(18-75 years) Participants in the MiniMed™ Advanced Hybrid
Closed-Loop (AHCL) System Pivotal Trial" – oral presentation by
John Shin, Ph.D., MBA, on
Friday, June 4 at 10:45 a.m. CT (17:45
CET).
- "Real-world outcomes of the first 1,000 users of the MiniMed™
780G system" – oral presentation by Ohad
Cohen, M.D. on Friday, June 4
from 1:30 p.m. CT (20:30 CET).
- "Cost-effectiveness analysis of the MiniMed™ 780G system versus
multiple daily injections with intermittently scanned continuous
glucose monitoring in individuals with type 1 diabetes in
Sweden" – poster presentation by
Ohad Cohen, M.D.
- "Real-world performance of the MiniMed™ 780G system: Impact of
initiating automated basal and bolus corrections" – poster
presentation by Julien Da Silva,
MSc.
Continuous Glucose Monitor
- "Performance of the Guardian™ Sensor (3) Continuous Glucose
Monitoring System with No Calibration" – oral presentation by
Ron Brazg, M.D., FACE, on
Wednesday, June 2 at 12:15 p.m. CT (19:15
CET).
Extended Wear Infusion Set Poster
Presentations
- "Feasibility clinical study assessing the compatibility of
Fiasp® insulin with Medtronic Extended Wear Infusion Set" – oral
presentation by Amir Tirosh, Ph.D.,
M.D., on Thursday, June 3 at
2:10 p.m. CT (21:10 CET).
- "Fiasp® Insulin Stability in Closed-Loop Insulin Pumps and the
Extended Wear Infusion Set" - poster presentation by Jenny Fusselman, MSc.
- "The Medtronic Extended Wear Infusion Set: Determining
mechanisms of action" - poster presentation by Sarnath Chattaraj,
Ph.D., senior research director, Medtronic.
Automated Insulin Pump System Poster
Presentations
- "Cost-effectiveness analysis of the MiniMed™ 670G versus
multiple daily injections with intermittently scanned continuous
glucose monitoring in individuals with type 1 diabetes in
the Netherlands" - oral
presentation by Erik Serné, M.D., Ph.D., on Wednesday, June 2 at 2
p.m. CT (21:00 CET).
- "A feasibility study assessing an "I-am-Eating" meal-bolus
option for a closed-loop system which eliminates carbohydrate
counting" – poster presentation by Amir
Tirosh, Ph.D., M.D.
- "1-year sustainability of real-world MiniMed™ 670G system
outcomes in Europe" - poster
presentation by Julien Da Silva,
MSc.
- "Algorithm-driven personalized insulin delivery: Insights from
real-world use and performance of the MiniMed™ 670G system in
Europe" – poster presentation by
Ohad Cohen, M.D.
- "Real-world performance of the MiniMed™ 670G system across
Europe and in South Africa" – poster presentation by
Julien Da Silva, MSc.
Smart Insulin Pens
- "Device and feature utilization in new InPen™ smart insulin pen
users who received virtual support" – poster presentation by
Madison B. Smith, Ph.D., R.N.
Other
- "Older adults with type 1 diabetes: Glucose outcomes with
technology and education" – poster presentation by Sybil McAuley, MBBS, Ph.D., FRACP.
Medtronic Sponsored Events
The following symposium and
three workshops will feature detailed clinical trial data and
discussions with Medtronic and independent speakers. Details are as
follows:
- "MiniMed™ 780G System: Improving Clinical Outcomes while
Reducing Diabetes Management Burden" chaired by Chantal Mathieu, M.D., Ph.D. on Wednesday, June 2, 10:00-11:30 a.m. CT (17:00-18:30 CET). Panelist and data to be
presented will include:
Chantal Mathieu,
M.D., Ph.D.
|
The Role of
Technology in Type 1 Diabetes Beyond the Pandemic
|
Ohad Cohen, M.D.,
director, medical affairs, Medtronic
|
The MiniMed™ 780G
System: Real-Word Evidence from the First 4,000 Users
|
Goran Petrovski,
M.D., MSc, Ph.D.
|
From MDI Therapy to
Automated Insulin Delivery Systems: Clinical Evidence
|
Bruce A. Buckingham,
M.D.
|
Innovation in
Infusion Sets: Extending the Wear for a Better
Experience
|
David Dunleavy, vice
president, portfolio management, Medtronic
|
Looking Toward the
Future: Next Steps in the Advancement of Closing the
Loop
|
- "Remote Onboarding of Advanced Technology" chaired by
Ohad Cohen, M.D. and Giovanni Annuzzi, M.D. on Thursday, June 3, 10:15 – 11:45 a.m. CT (17:15-18:45
CET). Panelist and speakers to include:
Giovanni Annuzzi,
M.D.
|
The Remote Onboarding
Program: A Physician Point of View
|
Lutgarda Bozzetto,
M.D., Ph.D.
|
Outcomes Achieved
with Remote Onboarding
|
Ohad Cohen,
M.D.
Lutgarda Bozzetto,
M.D., Ph.D.
Mauro Cammarosano,
senior training therapy specialist, Medtronic
|
Opportunities and
Challenges of a Remote Onboarding
|
Natalie García Heil,
patient onboarding program manager, Medtronic
|
Remote Onboarding:
Tools, Resources and Patients' Feedback
|
Rainer
Strassburger-Lausen, senior education program manager,
Medtronic
|
Practical Session 1:
Preparation of A Remote Training
|
Rainer
Strassburger-Lausen
|
Practical Session 2:
Using MiniMed™ 780G Virtual Demonstration in Remote
Training
|
- "How Smart Insulin Pens in Combination with CGM Insights can
Improve Diabetes Management" chaired by Janice MacLeod, M.A., R.D., CDCES, FADCES, head
of clinical advocacy, professional affairs and clinical education,
Medtronic, on Thursday, June 3, 1:30
– 2:30 p.m. CT (20:30-21:30 CET). Panelist and speakers to
include:
Andrew Rhinehart,
M.D., senior medical director, Medtronic
|
Real World Evidence
Review
|
Janice
MacLeod
|
Introducing the Smart
Insulin Pen Device
|
Janice
MacLeod
|
Introducing the
Integrated Smart Diabetes Management App
|
Anders Carlson,
M.D.
|
Introducing Smart MDI
Therapy and Overview of the Integrated Insights by InPen™ Data
Reports
|
- "Successfully Initiating MiniMed™ 780G System: A Structured
10-Days Protocol" chaired by Ohad
Cohen, M.D. on Friday, June 4,
10:15 – 11:45 a.m. CT (17:15-18:45 CET). Dr. Cohen will speak with
Goran Petrovski, M.D., MSc, Ph.D.
about the 10-Days Initiation Program and Clinical Evidence of
MiniMed™ 780G System and practical cases.
About the Diabetes Business at Medtronic
(www.medtronicdiabetes.com)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic plc (www.medtronic.com),
headquartered in Dublin, Ireland,
is among the world's largest medical technology, services and
solutions companies – alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 90,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission.
Actual results may differ materially from anticipated
results.
Contacts:
|
|
Kendra
Cassillo
|
Ryan
Weispfenning
|
Public
Relations
|
Investor
Relations
|
+1-818-576-5611
|
+1-763-505-4626
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/medtronic-announces-scientific-data-presentations-at-the-14th-international-conference-on-advanced-technologies--treatments-for-diabetes-301302969.html
SOURCE Medtronic plc